Viewing Study NCT06464068

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:37 PM
Ignite Modification Date: 2026-01-22 @ 8:16 AM
Study NCT ID: NCT06464068
Status: RECRUITING
Last Update Posted: 2024-06-18
First Post: 2024-06-07
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Extrapulmonary Small Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None EXTRAPULMONARY SMALL CELL CARCINOMA (EPSCC) View
None DURVALUMAB View